Newsfile Corp
08 Aug 2026, 10:19 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is accused in a securities class action of using channel stuffing to artificially inflate revenue. — Allegations of revenue manipulation via channel stuffing are severe and typically lead to significant stock price devaluation and loss of investor trust.
-0.80A lawsuit claims ADMA Biologics failed to disclose a related party transaction and lacked adequate internal controls. — Poor internal controls and undisclosed related party transactions suggest corporate governance failures and potential financial reporting risks.
-0.60The deadline for investors to move the Court to serve as lead plaintiff in the ADMA Biologics class action is August 10, 2026. — While a procedural deadline, it signals the active progression of litigation that could result in financial settlements.
-0.10Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is mentioned as being subject to a securities class action lawsuit.
The company is facing a securities class action lawsuit alleging channel stuffing, undisclosed related party transactions, and lack of internal controls.
The company is mentioned as being subject to a securities class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
1h ago
